Key Highlights

  • Third quarter Revenue rose 13% to USD 180.3 million, ahead of the USD 165.7 million estimate.
  • EPS of USD 0.14 beat the USD 0.09 estimate and compared with USD 0.06 a year earlier.
  • ORLADEYO net revenue reached USD 174.8 million, while non-GAAP operating profit rose to USD 86.5 million.
  • Total 2026 revenue guidance was raised to USD 715 million to USD 730 million at this quarter's update.

BioCryst (NASDAQ:BCRX) reported third quarter revenue of USD 180.3 million, up 13% from USD 159.4 million and above the USD 165.7 million estimate. Diluted EPS was USD 0.14, compared with the USD 0.09 estimate and USD 0.06 in the prior-year quarter. Net Income was USD 37.9 million, up from USD 12.9 million, and non-GAAP net income was USD 71.1 million against USD 34.7 million.

ORLADEYO Growth and Distribution Change

ORLADEYO revenue rose to USD 174.8 million from USD 159.1 million. License and other revenue was USD 5.5 million, up from USD 0.3 million. Revenue excluding European sales, which were divested on October 1, 2025, grew 24%. The quarter benefited from a transition to CareMed as the sole-source specialty pharmacy partner, which built an initial inventory of ORLADEYO. The company projects that inventory level to remain relatively stable, and said ORLADEYO revenue excluding Europe grew even after removing the inventory build.

Chief executive Charlie Gayer said the company launched ORLADEYO pellets in August for pediatric patients aged 2 to under 12. Early reimbursement is strong and new prescriptions are being filled ahead of plan. In October, the FDA approved the pellet formulation for patients aged 12 and older, giving prescribers a capsule or pellet option.

Profitability and Restructuring

Operating profit was USD 53.3 million against USD 29.6 million, and non-GAAP operating profit was USD 86.5 million against USD 50.8 million. GAAP Research and Development spending, excluding stock-based compensation, was USD 52.4 million, including USD 6.3 million of cash and USD 9.3 million of non-cash restructuring costs tied to the Birmingham site closure. Non-GAAP research and development was USD 37.1 million, compared with USD 38.0 million.

Sales and Marketing expenses were USD 37.7 million on a GAAP basis, down 15%, and USD 36.0 million non-GAAP, up 4% on specialty pharmacy transition fees. General and administrative expenses fell 22% to USD 21.0 million on a GAAP basis. The Birmingham closure carries about USD 10 million of cash costs and annualized savings of USD 30 million to USD 35 million once fully realized.

Cash, equivalents, restricted cash and investments totaled USD 376.4 million at September 30, 2026. For nine months, GAAP net loss was USD 605.5 million, reflecting USD 697.8 million of acquired in-process research and development from the Astria Therapeutics Acquisition in January.

Pipeline and 2026 Guidance

Top-line pivotal results for navenibart, a long-acting plasma kallikrein inhibitor studied in ALPHA-ORBIT, are scheduled for the third quarter of 2027. Initial Phase 1 data for BCX17725 in Netherton syndrome are scheduled by the end of 2026. The company discontinued STAR-0310, the early-stage atopic dermatitis program from Astria, to focus on rare diseases, and formed a seven-member Scientific Advisory Board.

BioCryst maintained 2026 ORLADEYO revenue guidance of USD 625 million to USD 645 million and raised total revenue guidance to USD 715 million to USD 730 million, up from USD 690 million to USD 715 million. The increase came mainly from navenibart licensing revenue and higher RAPIVAB orders from international partners. Non-GAAP Operating Expense guidance improved to USD 415 million to USD 425 million from USD 420 million to USD 440 million.

Next Reporting Checkpoints

Nine-month revenue of USD 555.0 million compares with the 2026 total revenue guide of USD 715 million to USD 730 million, while ORLADEYO nine-month revenue of USD 481.4 million compares with its full year guide of USD 625 million to USD 645 million. Non-GAAP operating profit of USD 86.5 million compares with USD 50.8 million a year earlier, and cash of USD 376.4 million compares with USD 37.9 million of quarterly net income.